Chang Hung-Yu, Lee Chi-Ming, Hung Chung-Lieh, Sung Shih-Hsien, Lin Tsung-Hsien, Wu Yen-Wen, Hwang Juey-Jen, Chen Wen-Jone, Wang Chun-Chieh
Institute of Hospital and Health Care Administration, and School of Medicine, College of Medicine, National Yang Ming Chiao Tung University and Heart Center, Cheng Hsin General Hospital.
Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei.
Acta Cardiol Sin. 2024 Mar;40(2):235-241. doi: 10.6515/ACS.202403_40(2).20230822A.
Heart failure (HF) is a significant public health problem worldwide. Death and rehospitalization rates are similar across different HF phenotypes. However, the existing Taiwanese HF registries mainly enrolled inpatients with HF and reduced ejection fraction (HFrEF) before 2019, so their results may not apply to outpatients or patients with HF with mildly reduced ejection fraction (HFmrEF) and HF with preserved ejection fraction (HFpEF) phenotypes.
The Taiwan Society of Cardiology Heart Failure Registry 2020 is a prospective, multicenter, observational registry that will enroll patients with HF from 27 hospitals in Taiwan between 2020 and 2022 and will be followed for two years. Patients eligible for enrollment include those admitted due to acute decompensated heart failure or outpatients with a history of hospitalization for heart failure within the past six months. The registry will collect patient demographics, medical history, HF diagnosis, medication use, examination results, and comorbidities. The registry plans to enroll 3,370 patients, with the distribution of HFrEF/HFmrEF/HFpEF as 59%/13%/28%. Follow-up intervals will occur every six months for up to two years to monitor clinical outcomes and major cardiac interventions. The registry will conclude in December 2024.
The Taiwan Society of Cardiology Heart Failure Registry 2020 is a comprehensive and meticulous effort to demonstrate the epidemiology, adherence to guidelines, clinical outcomes, and disease progression of Taiwanese patients with HF in contemporary clinical practice.
心力衰竭（HF）是全球范围内一个重大的公共卫生问题。不同HF表型的死亡率和再住院率相似。然而，现有的台湾HF登记处主要纳入2019年之前的住院HF患者及射血分数降低（HFrEF）患者，因此其结果可能不适用于门诊患者或射血分数轻度降低的HF（HFmrEF）患者以及射血分数保留的HF（HFpEF）表型患者。
2020年台湾心脏病学会心力衰竭登记处是一项前瞻性、多中心、观察性登记研究，将于2020年至2022年期间纳入台湾27家医院的HF患者，并进行为期两年的随访。符合纳入条件的患者包括因急性失代偿性心力衰竭入院的患者或过去六个月内有心力衰竭住院史的门诊患者。该登记处将收集患者的人口统计学信息、病史、HF诊断、用药情况、检查结果和合并症。该登记处计划纳入3370名患者，HFrEF/HFmrEF/HFpEF的分布比例为59%/13%/28%。随访间隔为每六个月一次，最长两年，以监测临床结局和主要心脏干预措施。该登记将于2024年12月结束。
2020年台湾心脏病学会心力衰竭登记处是一项全面且细致的工作，旨在展示当代临床实践中台湾HF患者的流行病学、指南遵循情况、临床结局和疾病进展。
